Antibodies Journal
Explore evitria’s Antibody Journal for in-depth articles on antibody engineering, CHO cell expression systems, and advancements in recombinant antibody production services.
Articles about Antibodies Journal (2)
-
Applications of recombinant proteins
Recombinant proteins literally come in various shapes. In this article, you will find out more about their numerous fields of application.
-
Application of recombinant DNA technology: What is rDNA used for?
Recombinant DNA is not only essential in the creation of recombinant antibodies. In this article, we will discover many other fields of application for rDNA.
-
Differences between monoclonal antibodies and recombinant monoclonal antibodies
There are some major differences between monoclonal and recombinant monoclonal antibodies – discover the most important ones in this article!
-
What are examples of bispecific drugs?
Bispecific drugs hold immense promise in revolutionizing therapeutic interventions across various medical fields. In this article, we explore three examples of bispecifics and their applications, illuminating their remarkable potential in advancing patient care.
-
What is the difference between a monoclonal and a bispecific antibody?
Both monoclonal and bispecific antibodies come with numerous benefits, but have several differences that set them apart. We will review them in this article.
-
Antibody-Dependent Cellular Cytotoxicity (ADCC) – Definition, Mechanism & Application
Antibody-dependent cellular cytotoxicity is a key process of the immune system’s arsenal to ward off cancerous cells and infections. We show you important definitions and the ADCC mechanism and key facts on ADCC antibodies in this post.
-
Speed vs. Quality in Early Drug Development: Striking the Right Balance for Antibody Therapeutics
In drug development, speed without reproducibility risks costly setbacks. This article shows how high-quality antibody materials, early testing, and smart design enable faster, more reliable programs without compromising rigor.
-
Why Promising Antibody Candidates Fail Before Clinical Trials – and How to Avoid It
Despite strong market growth, most antibody candidates fail early due to developability, pharmacokinetics, or immunogenicity issues. This article outlines key risks and strategies to de-risk development and speed the path from discovery to IND.
-
Fast-Tracking Bispecific Antibody Development: What Can Go Wrong?
Bispecific antibodies hold great promise, but rushing development can trigger design and manufacturing risks. This article explores how smart strategies and expert partnerships accelerate bsAb programs without compromising quality.
-
The Risks of Over-Promising in Early-Stage Biologics Development
In early biologics development, over-promising can derail programs and erode trust. This article explores the causes, consequences, and how data-driven planning safeguards progress and credibility.
-
The Stability Problem: Why Some Recombinant Antibodies Don’t Make It to Market
Stability is key to antibody success, but physical, chemical, and biological issues often derail candidates. This article covers causes, consequences, and strategies to improve stability, manufacturability, and speed development to market.
-
Afucosylated recombinant antibodies
Generally speaking, antibodies of any kind, including recombinant and afucosylated antibodies, are Y-shaped proteins produced by the human body. As they are able to identify and neutralize foreign objects – in other words viruses – they play a major contributing role in keeping our body and immune system healthy.